

[How I treat cancer-associated anemia.](#)

Gilreath JA, Rodgers GM. *Blood*. 2020 Aug;**136**(7): 801-813.

[miR-125a-5p regulates megakaryocyte proplatelet formation via the actin bundling protein L-plastin.](#)

Bhatlekar S, Manne BK, Basak I, Edelstein LC, Tugolukova E, Stoller ML, Cody MJ, Morley SC, Nagalla S, Weyrich AS, Rowley JW, O'Connell RM, Rondina MT, Campbell RC, **Bray PF**. *Blood*. 2020, *In Press*.

[Dasatinib Overcomes Stroma-Based Resistance to the FLT3 Inhibitor Quizartinib Using Multiple Mechanisms.](#)

**Patel AB**, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, **Tantravahi SK**, **Kovacovics T**, **Shami PJ**, **O'Hare T**, **Deininger MW**. *Leukemia*. 2020 May; *In Press*.

[FBXL5 regulates IRP2 stability in iron homeostasis via an oxygen-responsive \[2Fe2S\] cluster.](#)

Wang h, ShiH, Rajan M, Canarie ER, Hong S, Simoneschi D, Pagano M, Bush MF, Stoll S, **Leibold EA**, Zheng N. *Mol Cell*. 2020 Apr;**78**(1):31-41.e5. PMID: PMC7159994.

[Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit.](#)

Gordeuk VR, Miasnikova GY, Sergueeva AJ, Lorenzo FR, Zhang X, Song J, Stockton DW, **Prchal JT**. *Haematologica*. 2020 Mar;**105**(3):e87-e90. PMID: PMC7049338.

[Late Effects After Ablative Allogeneic Stem Cell Transplantation for Adolescent and Young Adult Acute Myeloid Leukemia.](#)

**Lee CH**, Kim S, Tecca HR, Bo-Subait S, Phelan R, Brazauskas, R, et al. *Blood Adv*. 2020 Mar;**4**(6):983-992. PMID: PMC7094022.

[Cysteine toxicity drives age-related mitochondrial decline 1 by altering iron 2 homeostasis.](#)

Hughes CE, Coody TK, Jeong M-Y., Berg JA, **Winge DR**, Hughes AL. *Cell*. 2020 Jan;**180**(2):296-310 PMID: PMC7164368.

[JAK2 ex13InDel Drives Oncogenic Transformation and Is Associated With Chronic Eosinophilic Leukemia and Polycythemia Vera.](#)

**Patel AB**, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, **O'Hare T**, **Prchal JT**, **Deininger MW**. *Blood*. 2019 Dec;**134**(26):2388-2398. PMID: PMC6933291.

[A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.](#)

Mascarenhas J, Kosiorek H, **Prchal J**, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R. *Leukemia*. 2019 Dec;**33**(12):2974-2978. PMID: PMC6884668.

[JAK2ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.](#)

Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann M, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu S, **O'Hare T, Prchal JT, Deininger MW**. *Blood*. 2019 Dec;**134**(26):2388-2398 PMID: PMC6933291.

[Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma's cyclin D1.](#)

Babosova O, Kapralova K, Raskova Kafkova L, Korinek V, Divoky V, **Prchal JT**, Lanikova L. *J of Cell Mol Med*. 2019 Nov;**23**(11):7785-7795. PMID: PMC6815829.

[Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.](#)

**Stephens DM**. *Blood*. 2019 Nov;**134**(20):1691-1696. PMID: 31488409.

[Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.](#)

**Hu B**, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. *Br J Haematol*. 2019 Nov;**187**(3):307-318. PMID: 31243771.

[Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.](#)

Din L, Sheikh M, Kosaraju N, Smedby KE, Bernatsky S, Berndt SI, Skibola CF, Nieters A, Wang S, McKay JD, Cocco P, Maynadié M, Foretová L, Staines A, Mack TM, de Sanjosé S, Vyse TJ, Padyukov L, Monnereau A, Arslan AA, Moore A, Brooks-Wilson AR, Novak AJ, Glimelius B, Birmann BM, Link BK, Stewart C, Vajdic CM, Haioun C, Magnani C, Conti DV, Cox DG, Casabonne D, Albanes D, Kane E, Roman E, Muzi G, Salles G, Giles GG, Adami HO, Ghesquières H, De Vivo I, Clavel J, Cerhan JR, Spinelli JJ, Hofmann J, Vijai J, Curtin K, Costenbader KH, Onel K, Offit K, Teras LR, Morton L, Conde L, Miligi L, Melbye M, Ennas MG, Liebow M, Purdue MP, Glenn M, Southey MC, Din M, Rothman N, **Camp NJ**, Wong Doo N, Becker N, Pradhan N, Bracci PM, Boffetta P, Vineis P, Brennan P, Kraft P, Lan Q, Severson RK, Vermeulen RCH, Milne RL, Kaaks R, Travis RC, Weinstein SJ, Chanock SJ, Ansell SM, Slager SL, Zheng T, Zhang Y, Benavente Y, Taub Z, Madireddy L, Gourraud PA, Oksenberg JR, Cozen W, Hjalgrim H, Khankhanian P. *Genet Epidemiol*. 2019 Oct;**43**(7):844-863. PMID: PMC6763347.

[Anti-apoptotic BCL2L2 increases megakaryocyte proplatelet formation in cultures of human cord blood.](#)

Bhatlekar S, Basak I, Edelstein LC, Campbell RA, Lindsey CR, Italiano JE Jr, Weyrich AS, Rowley JW, Rondina MT, Sola-Visner M, **Bray PF**. *Haematologica*. 2019 Oct;**104**(10):2075-2083. PMID: PMC6886406.

[Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.](#)

Yacoub A, Mascarenhas J, Kosiorek H, **Prchal JT**, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R. *Blood*. 2019 Oct;**134**(18):1498-1509. PMID: PMC6839950.

[Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants.](#)

Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, **O'Hare T**, Druker BJ, **Deininger MW**. **Cancer Cell**. 2019 Oct;**36**(4):431-443.e5. PMID: PMC6893878.

[Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach for stage III/IV Hodgkin lymphoma.](#)

**Stephens DM**, Li H, Schöder H, Straus DJ, Moskowitz CH, Leblanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi E, Leonard JP, Kahl B, Smith SM, Friedberg JW. **Blood**. 2019 Oct;**134**(15):1238-1246. PMID: PMC6788007.

[Curated disease-causing genes for bleeding, thrombotic, and platelet disorders: communication from the SSC of the ISTH.](#)

Megy K, Downes K, Simeoni I, Bury L, Morales J, Mapeta R, Bellissimo DB, **Bray PF**, Goodeve AC, Gresele P, Lambert M, Reitsma P, Ouwehand WH, Freson K; Subcommittee on Genomics in Thrombosis and Hemostasis. **J Thromb Haemost**. 2019 August;**17**(8):1253-1260. PMID: PMC6852472.

[Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.](#)

**Hu B**, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. **Br J Haematol**. 2019, June;**185**(5):852-864. PMID: 30924136.

[Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3.](#)

Campbell RA, Schwertz H, Hottz ED, Rowley JW, Manne BK, Washington AV, Hunter-Mellado R, Tolley ND, Christensen M, Eustes AS, Montenont E, Bhatlekar S, Ventrone CH, Pierce KK, Whitehead SS, Diehl SA, **Bray PF**, Zimmerman GA, Kosaka Y, Bozza PT, Bozza FA, Weyrich AS, Rondina MT. **Blood**. 2019 May;**133**(19):2013-2026. PMID: PMC6509546.

[Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations.](#)

**Patel AB**, Pettijohn EM, Abedin SM, Raps E, **Deininger MW**. **Blood Adv**. 2019 Apr;**3**(7):952-955. PMID: PMC6457233.

[Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis.](#)

Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton W, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, **Prchal JT**, **O'Hare T**, **Deininger MW**. **Clin Cancer Res**. 2019 Apr;**25**(7): 2323-2335. PMID: PMC6445677.

[miR-15a-5p regulates expression of multiple proteins in the megakaryocyte GPVI signaling pathway.](#)

Basak I, Bhatlekar S, Manne BK, Stoller M, Hugo S, Kong X, Ma L, Rondina MT, Weyrich AS, Edelstein LC, **Bray PF**. *J Thromb Haemost*. 2019 Mar;**17**(3): 511-524. PMID: PMC6397079.

[Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees.](#)

**Glenn MJ**, Madsen MJ, Davis E, Garner CD, Curtin K, Jones B, Williams JA, Tomasson MH, **Camp NJ**. *Blood Cancer J*. 2019 Feb;**9**(3):25. PMID: PMC6391432.

[Diagnosing or ruling out polycythemia vera in patients with erythrocytosis.](#)

**Prchal JT**. *Clin Adv Hematol Oncol*. 2019 Jan;**17**(1):24-27. PMID: 30843892.

[Functional genomic landscape of acute myeloid leukaemia.](#)

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempfer A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, **Deininger MW**, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ. *Nature*. 2018 Oct;**562**(7728):526-531. PMID: PMC6280667.

[Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.](#)

Kleinstern G, **Camp NJ**, Goldin LR, Vachon CM, et al. *Blood*. 2018 Jun;**131**(23):2541-2551. PMID: PMC5992865.

[Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.](#)

Law PJ, Berndt SI, Speedy HE, **Camp NJ**, et al. *Nat Commun*. 2017 Feb;**8**:14175. PMID: PMC5303820.